Status:
TERMINATED
VAC Bioburden Wound Care Assessment
Lead Sponsor:
Duke University
Collaborating Sponsors:
3M
Conditions:
Upper Extremity Wound
Lower Extremity Wound
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to compare the microbiologic burden and need for further operative debridement of patients undergoing primary surgical debridement of infected tissue, soft tissue abscesse...
Detailed Description
Bacterial bio-burden as measured by quantitative microbial PCR prior to debridement, immediately following initial debridement, after 2 days of VAC veraflo (or conventional VAC) therapy, and at the ti...
Eligibility Criteria
Inclusion
- 18+yo with an injury or infection of the upper or lower extremity for which surgical debridement (in the operating room) followed by VAC application is planned.
Exclusion
- \- Patient with wounds distal to the ankle.
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 13 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04826965
Start Date
August 1 2021
End Date
October 13 2022
Last Update
November 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University
Durham, North Carolina, United States, 27710